Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma



Status:Recruiting
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/6/2019
Start Date:February 2015
End Date:October 2022
Contact:Acerta Call center
Email:acertamc@dlss.com
Phone:1-888-292-9613

Use our guide to learn which trials are right for you!

An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with
rituximab in subjects with R/R FL.

Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab
in subjects with R/R MZL, as measured by ORR.

Part 3 and 4: To characterize the safety of acalabrutinib in combination with rituximab and
lenalidomide in subjects with R/R FL or R/R non-GCB DLBCL

An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects
with B-cell Non-Hodgkin Lymphoma

Inclusion Criteria:

- Men and women ≥ 18 years of age.

- Part 1: A confirmed diagnosis of FL Grade 1, 2, or 3a, which has relapsed after, or
been refractory to ≥ 1 prior therapy for FL, or subjects who have not previously
received systemic anticancer therapy for FL., and which requires treatment.

- Part 2:Histologically confirmed MZL including splenic, nodal, and extranodal sub-
types

1. Subjects with splenic MZL must have an additional measurable lesion, nodal or
extranodal, as described in inclusion criterion #4;

2. Subjects with gastric mucosa-associated lymphoid tissue (MALT) lymphoma must be
Helicobacter pylori (HP)-negative

- Part 3: For subjects with FL: Pathologically confirmed diagnosis of FL Grade 1, 2, or
3a, which has relapsed after, or been refractory to ≥ 1 prior therapy for FL and which
requires treatment per National Cancer Institute or ESMO clinical practice guidelines.

- Part 4: For subjects with non-GCB DLBCL: Pathologically confirmed de novo non- GCB
DLBCL based on local IHC using Hans algorithm (Hans 2004) or else subjects must have
available archival tissue for central pathology review to be eligible

- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.

- Agreement to use contraception during the study and for 30 days after the last dose of
study drugs if sexually active and able to bear or beget children.

Exclusion Criteria:

- •A life-threatening illness, medical condition or organ system dysfunction which, in
the investigator's opinion, could compromise the subject's safety, interfere with the
absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk

- Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias,
congestive heart failure, or myocardial infarction within 6 months of screening, or
any Class 3 or 4 cardiac disease as defined by the New York Heart Association
Functional Classification, or Qtc >480 msec

- Malabsorption syndrome, disease significantly affecting gastrointestinal function, or
resection of the stomach or small bowel, gastric bypass, symptomatic inflammatory
bowel disease, or partial or complete bowel obstruction.

- Breast feeding or pregnant
We found this trial at
11
sites
Louisville, Kentucky 40202
Principal Investigator: Don Stevens, MD
?
mi
from
Louisville, KY
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
Principal Investigator: Sonali Smith, MD
Phone: 773-834-4574
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Principal Investigator: Parameswaran Venugopal, MD
Phone: 312-942-3309
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Beth Christian, MD
Phone: 614-366-0855
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Duarte, California 91010
Principal Investigator: Robert Chen, MD
Phone: 626-218-4632
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Lake Success, New York 11042
Principal Investigator: Morton Coleman, MD
?
mi
from
Lake Success, NY
Click here to add this to my saved trials
New York, New York 10021
?
mi
from
New York, NY
Click here to add this to my saved trials
Salt Lake City, Utah 84112
Principal Investigator: Deborah Stephens, MD
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Whittier, California 90603
?
mi
from
Whittier, CA
Click here to add this to my saved trials